世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

てんかん治療薬の市場規模・予測（2020年～2030年）、治療薬別（第一世代抗てんかん薬、第二世代抗てんかん薬、第三世代抗てんかん薬）、流通チャネル別（病院薬局、小売薬局店舗、その他）、地域別（北米、欧州、アジア太平洋地域、中東・アフリカ、中南米）の世界・地域シェア、動向、成長機会分析


Epilepsy Drugs Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

てんかん治療薬の市場規模は、2022年に77億6800万米ドルと評価され、2030年には107億500万米ドルに達すると予測され、2022年から2030年までの年平均成長率は4.1%と推定される。てんかん治療薬市場の成長は、主に... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
The Insight Partners
ザ・インサイトパートナーズ 		2023年11月6日 US$4,550
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		139 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

てんかん治療薬の市場規模は、2022年に77億6800万米ドルと評価され、2030年には107億500万米ドルに達すると予測され、2022年から2030年までの年平均成長率は4.1%と推定される。てんかん治療薬市場の成長は、主にてんかんの有病率の増加と高齢者の増加によってもたらされる。

てんかんは発作を引き起こす神経疾患で、世界的に数百万人が罹患している。てんかん治療薬は抗てんかん薬（AED）としても知られており、てんかん患者の発作をよりよく管理するのに役立つため、てんかん治療に一般的に使用されています。薬物抵抗性てんかん患者の中には、手術や発作管理に役立つ脳内埋め込み型装置など、他の治療法を選択する人もいる。

特許切れ間近のてんかん治療薬がてんかん治療薬市場の成長機会を創出

てんかん治療薬市場では、今後数年間で多くの特許切れが予想される。医療費削減のためにジェネリック医薬品の普及が進む可能性が高い。これにより、他の市場プレーヤーにも新たなビジネスチャンスが生まれるだろう。以下に、今後数年で特許満了を迎える医薬品をいくつか紹介する。

会社名 特許満了日 成分 治療法

住友製薬株式会社 US9206135 2026年4月21日 エスリカルバゼピン 酢酸エステル 部分発作 てんかん

グラクソ・スミスクライン US7919115 2029年1月4日 ラモトリギン てんかん

Ucb Inc USRE38551 2022年3月17日 ラコサミド てんかん・部分発作

SK Biopharmaceuticals US7598279 2027年10月30日 セノバメート 部分てんかん

トピラマートの徐放性製剤 てんかん治療剤

US9555004 2027年11月 トピラマートの徐放性製剤 てんかん

トピラマートの徐放性製剤 てんかん治療剤

US8663683 2027年11月 トピラマート持続放出型てんかん治療剤

US9622983 2027年11月 トピラマート持続放出型てんかん治療剤

US8298580 2027年11月 トピラマート持続放出型てんかん治療剤

US8992989 2027年11月 トピラマート持続放出型てんかん治療剤

US8889191 2027年11月 トピラマート持続放出型てんかん治療剤

トピラマートの徐放性製剤 てんかん治療剤

トピラマートの徐放性製剤 てんかん治療剤

治療に基づく洞察

てんかん治療薬市場は、治療薬別に第一世代抗てんかん薬、第二世代抗てんかん薬、第三世代抗てんかん薬に区分される。2022年には、第二世代抗てんかん薬セグメントが最大の市場シェアを占め、2022～2030年には第三世代抗てんかん薬が最も速いCAGRを記録すると推定される。第2世代AEDには、フェルバメート、ガバペンチン、ラモトリギン、レベチラセタム、オクスカルバゼピン、プレガバリン、ルフィナミド、スルピペントール、チアガビン、トピレート、トピラマート、ビガバトリン、ゾニサミドが含まれる。北米と欧州では、ZNSも第2世代の薬剤とみなされている。第二世代AEDは第一世代AEDと比較して高価であることが、処方箋への記載を制限する大きな要因となっている。第二世代AEDは、第一世代と比較して副作用プロファイルが良好で、催奇形性のリスクも低い。多くの第一世代といくつかの第二世代（AED）には、酵素誘導作用という共通の特徴があり、誘導剤の作用の低下とともに、チトクロームp450酵素が標的とするさまざまな基質の代謝を増加させることができる。

流通経路に基づく洞察

てんかん治療薬市場は、流通チャネル別に病院薬局、小売薬局、その他に区分される。2022年には、病院薬局セグメントが最大の市場シェアを占め、小売薬局セグメントは2022～2030年に最も速いCAGRを記録すると予測されている。病院薬局は、さまざまな企業から医薬品を購入し、外来患者または入院患者の治療のために病院に供給する。病院薬局は通常、心臓病学、神経学、泌尿器学、病理学、血液学、皮膚科学に応用される治療薬や重症治療薬を提供している。病院薬局は、どの国の医療システムにも欠かせない存在です。これらの薬局では、てんかん治療薬の在庫を管理し、患者がすぐに利用できるようにしている。そのため、病院薬局はてんかん治療薬市場のかなりの規模を占めている。

てんかん治療薬市場に関する本レポートの作成にあたり、世界保健機関（WHO）、米国疾病予防管理センター（CDC）、米国国立生物工学情報センター（NCBI）、投資家向けプレゼンテーション、市場参入企業の年次報告書などの主要な一次情報源および二次情報源を参照した。



ページTOPに戻る


目次

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Epilepsy Drugs Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Epilepsy Drugs Market - Key Industry Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Epilepsy
5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
5.4.1 Increasing Product Approvals
5.5 Impact Analysis
6. Epilepsy Drugs Market - Global Market Analysis
6.1 Epilepsy Drugs Revenue (US$ Mn), 2022 – 2030
7. Global Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Treatment
7.1 Overview
7.2 Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
7.3.1 Overview
7.3.2 First Generation Antiepileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
7.4.1 Overview
7.4.2 Second Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
7.5.1 Overview
7.5.2 Third Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8. Global Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
8.4.1 Overview
8.4.2 Retail Pharmacy Stores: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9. Epilepsy Drugs Market – Revenue and Forecast to 2030 – Geographic Analysis
9.1 North America: Epilepsy Drugs Market
9.1.1 Overview
9.1.2 North America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3 North America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4 North America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.1 US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.1.1 Overview
9.1.4.1.2 US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.1.3 US: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.1.4 US: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.2 Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.2.1 Overview
9.1.4.2.2 Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.2.3 Canada: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.2.4 Canada: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.3 Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.3.1 Overview
9.1.4.3.2 Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.3.3 Mexico: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.3.4 Mexico: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2 Europe: Epilepsy Drugs Market
9.2.1 Overview
9.2.2 Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3 Europe: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.4 Europe: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5 Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.2.5.1 Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.1.1 Overview
9.2.5.1.2 Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.1.3 Germany: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.1.4 Germany: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.2 France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.2.1 Overview
9.2.5.2.2 France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.2.3 France: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.2.4 France: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.3 UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.3.1 Overview
9.2.5.3.2 UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.3.3 UK: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.3.4 UK: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.4 Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.4.1 Overview
9.2.5.4.2 Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.4.3 Italy: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.4.4 Italy: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.5 Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.5.1 Overview
9.2.5.5.2 Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.5.3 Spain: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.5.4 Spain: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.6 Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.6.1 Overview
9.2.5.6.2 Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.6.3 Rest of Europe: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.6.4 Rest of Europe: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3 Asia Pacific: Epilepsy Drugs Market
9.3.1 Overview
9.3.2 Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.3.3 Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.4 Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5 Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.3.5.1 China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.1.1 Overview
9.3.5.1.2 China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.1.3 China: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.1.4 China: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.2 Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.2.1 Overview
9.3.5.2.2 Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.2.3 Japan: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.2.4 Japan: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.3 India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.3.1 Overview
9.3.5.3.2 India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.3.3 India: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.3.4 India: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.4 Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.4.1 Overview
9.3.5.4.2 Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.4.3 Australia: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.4.4 Australia: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.5 South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.5.1 Overview
9.3.5.5.2 South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.5.3 South Korea: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.5.4 South Korea: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.6 Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.6.1 Overview
9.3.5.6.2 Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.6.3 Rest of Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.6.4 Rest of Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4 Middle East & Africa Epilepsy Drugs Market
9.4.1 Overview
9.4.2 Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3 Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4 Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.1 South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.1.1 Overview
9.4.4.1.2 South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.1.3 South Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.1.4 South Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.2 Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.2.1 Overview
9.4.4.2.2 Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.2.3 Saudi Arabia: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.2.4 Saudi Arabia: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.3 UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.3.1 Overview
9.4.4.3.2 UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.3.3 UAE: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.3.4 UAE: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.4.1 Overview
9.4.4.4.2 Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.4.3 Rest of Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5 South & Central America: Epilepsy Drugs Market
9.5.1 Overview
9.5.2 South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.5.3 South & Central America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.4 South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5 South & Central America: Epilepsy Drugs Market Share by Country – 2022 & 2030, (%)
9.5.5.1 Brazil: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.1.1 Overview
9.5.5.1.2 Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.5.5.1.3 Brazil: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.1.4 Brazil: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5.2 Argentina: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.2.1 Overview
9.5.5.2.2 Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.5.5.2.3 Argentina: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.2.4 Argentina: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5.3 Rest of South & Central America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.3.1 Overview
9.5.5.3.2 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.5.5.3.3 Rest of South & Central America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.3.4 Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
10. Epilepsy Drugs Market–Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 UCB SA
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Novartis AG
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Pfizer Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 GSK Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Abbott Laboratories
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Sanofi SA
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Sumitomo Pharma America Inc.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Catalyst Pharmaceuticals Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Alkem Laboratories Ltd
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms

　

ページTOPに戻る


　

Summary

The epilepsy drugs market size was valued at US$ 7.768 billion in 2022 and is projected to reach US$ 10.705 billion by 2030; it is estimated to register a CAGR of 4.1% from 2022 to 2030. The epilepsy drugs market growth is primarily driven by the increasing prevalence of epilepsy and an increasing number of elderly people.

Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.

Several Epilepsy Drugs Nearing Patent Expiration Creating Opportunities for Epilepsy Drugs Market Growth

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

Treatment-Based Insights

The epilepsy drugs market, by treatment, is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022–2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer.

Distribution Channel-Based Insights

The epilepsy drugs market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022–2030. Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drug market.

A few of the major primary and secondary sources referred to while preparing the report on the epilepsy drugs market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Investor presentations and Annual Reports of Market players.



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Epilepsy Drugs Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Epilepsy Drugs Market - Key Industry Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Epilepsy
5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
5.4.1 Increasing Product Approvals
5.5 Impact Analysis
6. Epilepsy Drugs Market - Global Market Analysis
6.1 Epilepsy Drugs Revenue (US$ Mn), 2022 – 2030
7. Global Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Treatment
7.1 Overview
7.2 Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
7.3.1 Overview
7.3.2 First Generation Antiepileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
7.4.1 Overview
7.4.2 Second Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
7.5.1 Overview
7.5.2 Third Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8. Global Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
8.4.1 Overview
8.4.2 Retail Pharmacy Stores: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9. Epilepsy Drugs Market – Revenue and Forecast to 2030 – Geographic Analysis
9.1 North America: Epilepsy Drugs Market
9.1.1 Overview
9.1.2 North America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3 North America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4 North America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.1 US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.1.1 Overview
9.1.4.1.2 US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.1.3 US: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.1.4 US: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.2 Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.2.1 Overview
9.1.4.2.2 Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.2.3 Canada: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.2.4 Canada: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.3 Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.3.1 Overview
9.1.4.3.2 Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.3.3 Mexico: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.3.4 Mexico: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2 Europe: Epilepsy Drugs Market
9.2.1 Overview
9.2.2 Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3 Europe: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.4 Europe: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5 Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.2.5.1 Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.1.1 Overview
9.2.5.1.2 Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.1.3 Germany: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.1.4 Germany: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.2 France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.2.1 Overview
9.2.5.2.2 France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.2.3 France: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.2.4 France: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.3 UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.3.1 Overview
9.2.5.3.2 UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.3.3 UK: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.3.4 UK: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.4 Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.4.1 Overview
9.2.5.4.2 Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.4.3 Italy: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.4.4 Italy: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.5 Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.5.1 Overview
9.2.5.5.2 Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.5.3 Spain: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.5.4 Spain: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.6 Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.6.1 Overview
9.2.5.6.2 Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.6.3 Rest of Europe: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.6.4 Rest of Europe: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3 Asia Pacific: Epilepsy Drugs Market
9.3.1 Overview
9.3.2 Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.3.3 Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.4 Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5 Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.3.5.1 China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.1.1 Overview
9.3.5.1.2 China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.1.3 China: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.1.4 China: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.2 Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.2.1 Overview
9.3.5.2.2 Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.2.3 Japan: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.2.4 Japan: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.3 India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.3.1 Overview
9.3.5.3.2 India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.3.3 India: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.3.4 India: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.4 Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.4.1 Overview
9.3.5.4.2 Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.4.3 Australia: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.4.4 Australia: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.5 South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.5.1 Overview
9.3.5.5.2 South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.5.3 South Korea: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.5.4 South Korea: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.6 Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.6.1 Overview
9.3.5.6.2 Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.6.3 Rest of Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.6.4 Rest of Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4 Middle East & Africa Epilepsy Drugs Market
9.4.1 Overview
9.4.2 Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3 Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4 Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.1 South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.1.1 Overview
9.4.4.1.2 South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.1.3 South Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.1.4 South Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.2 Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.2.1 Overview
9.4.4.2.2 Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.2.3 Saudi Arabia: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.2.4 Saudi Arabia: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.3 UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.3.1 Overview
9.4.4.3.2 UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.3.3 UAE: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.3.4 UAE: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.4.1 Overview
9.4.4.4.2 Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.4.3 Rest of Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5 South & Central America: Epilepsy Drugs Market
9.5.1 Overview
9.5.2 South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.5.3 South & Central America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.4 South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5 South & Central America: Epilepsy Drugs Market Share by Country – 2022 & 2030, (%)
9.5.5.1 Brazil: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.1.1 Overview
9.5.5.1.2 Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.5.5.1.3 Brazil: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.1.4 Brazil: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5.2 Argentina: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.2.1 Overview
9.5.5.2.2 Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.5.5.2.3 Argentina: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.2.4 Argentina: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5.3 Rest of South & Central America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.3.1 Overview
9.5.5.3.2 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.5.5.3.3 Rest of South & Central America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.3.4 Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
10. Epilepsy Drugs Market–Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 UCB SA
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Novartis AG
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Pfizer Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 GSK Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Abbott Laboratories
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Sanofi SA
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Sumitomo Pharma America Inc.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Catalyst Pharmaceuticals Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Alkem Laboratories Ltd
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（通信回線）の最新刊レポート

The Insight Partners 社の最新刊レポート

本レポートと同じKEY WORD（channel）の最新刊レポート


よくあるご質問


The Insight Partners社はどのような調査会社ですか?


The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/09/25　10:28

144.33 円

161.91 円

196.41 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.